Merck & Co., Inc. (MRK)
Healthcare · end-of-day data as of Oct 16, 2026
The average 12-month analyst price target for MRK is $155.89, 6.8% above the last close of $145.95 on Oct 16, 2026; targets range from $103.14 to $185.78. Rating consensus: Buy.
Snapshot
- P/E116.8x
- P/E vs sector+314.7%
- P/E vs own+187.9%
- Target upside+7.7%
- ConsensusBuy
- Market cap$360B
- FCF yield+4.5%
- Insiders-$25.58M
- Earnings in13d
- News
Why it moved
Merck & Co., Inc. (MRK) rose 0.5% on Oct 16, 2026.
The market (SPY) fell 1.1%; Healthcare stocks fell 0.7%. Most of the move is specific to MRK.
3 stories on the day (30-day average 3.1).
- Merck & Co., Inc. $MRK Stock: Banque Pictet & Cie SA Cuts Holdings
- Merck Stock: Watch This Price, Prepare To Profit From This Trade
- The Stocks That Will Get Investors Home Safe When Tech Cracks
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $145.95 · +79.0% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendbullish
- Sector▲ +16.0%
- MAs20▲ 50▲ 100▲ 200▲
- Above MAs4 of 4 above
- MA20×50↓ in ~3d
- RSI52
- Support-11.6%
- Resistance+3.6%
- Off 52w high-6.2%
- Off ATH-6.2%
- 52w range$145.95
- Bollingerupper half
- MACD-0.04
- ATR+2.6%
- Volume1.2x
Analyst price targets
19 firms with a target in the last 12 months · last close $145.95 · as of Oct 16, 2026
Strong buy 5 · Buy 14 · Hold 8 · Sell 0 · Strong sell 0
Revenue and free cash flow
Q2 FY2026: Revenue +5.1% year over year, free cash flow 27.0% of revenue, operating margin -4.1%.
| Q2 FY2026 | Jun 30, 2026 | $16.61B | -0.54 | $4.48B | 73.5% | -4.1% | -8.0% |
| Q1 FY2026 | Mar 31, 2026 | $16.29B | -1.72 | $2.93B | 81.9% | -11.6% | -26.0% |
| Q4 FY2025 | Dec 31, 2025 | $16.32B | 1.19 | $1.82B | 70.5% | 37.7% | 18.2% |
| Q3 FY2025 | Sep 30, 2025 | $17.18B | 2.32 | $6.83B | 75.6% | 43.4% | 33.7% |
| Q2 FY2025 | Jun 30, 2025 | $15.8B | 1.76 | $2.53B | 75.7% | 40.2% | 28.0% |
| Q1 FY2025 | Mar 31, 2025 | $15.62B | 2.01 | $1.17B | 75.1% | 43.0% | 32.5% |
| Q4 FY2024 | Dec 31, 2024 | $15.62B | 1.48 | $2.51B | 75.5% | 27.8% | 24.0% |
| Q3 FY2024 | Sep 30, 2024 | $16.66B | 1.24 | $8.51B | 75.5% | 23.9% | 19.0% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $1,257.03 | +0.4% | -1.8% | +4.5% | 42.2 | $1.18T | |
| 2 |  | $255.56 | +0.9% | -8.2% | +8.8% | 38.7 | $616B | |
| 3 |  | $285.42 | +0.7% | 0.0% | -1.4% | 80.4 | $504B | |
| 4 | | $145.95 | +0.5% | -6.2% | +7.7% | 116.8 | $360B | |
| 5 |  | $432.49 | -0.4% | -2.6% | -7.5% | 26.9 | $234B | |
| 6 |  | $156.19 | -0.7% | -0.7% | +1.9% | — | $194B | |
| 7 |  | $29.58 | +0.5% | 0.0% | -7.1% | 39.1 | $169B | |
| 8 |  | $59.75 | -1.4% | -11.3% | +9.4% | 13.2 | $122B |
Data as of Oct 16, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.